Highly Galactosylated Anti-IL-5 (Mepolizumab) Antibody (CAT#: BioBet-GA-018ZP) Datasheet

IL5

interleukin 5

This gene encodes a cytokine that acts as a growth and differentiation factor for both B cells and eosinophils. The encoded cytokine plays a major role in the regulation of eosinophil formation, maturation, recruitment and survival. The increased production of this cytokine may be related to pathogenesis of eosinophil-dependent inflammatory diseases. This cytokine functions by binding to its receptor, which is a heterodimer, whose beta subunit is shared with the receptors for interleukine 3 (IL3) and colony stimulating factor 2 (CSF2/GM-CSF). This gene is located on chromosome 5 within a cytokine gene cluster which includes interleukin 4 (IL4), interleukin 13 (IL13), and CSF2 . This gene, IL4, and IL13 may be regulated coordinately by long-range regulatory elements spread over 120 kilobases on chromosome 5q31

EDF; TRF; IL-5

Extracellular region or secreted

Its related pathways are RET signaling and Signaling by GPCR.

Factor that induces terminal differentiation of late-developing B-cells to immunoglobulin secreting cells.

1. Glycosylation at Thr22 and Asn47 2. Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

Mepolizumab

Human

Human

Mepolizumab is a humanized monoclonal antibody that specifically recognizes and blocks interleukin 5 (IL-5). It was used for the treatment of severe eosinophilic asthma and is used in combination with other drugs for asthma. Mepolizumab is now used to treat many other conditions, such as severe nasal polyps, adult eosinophilic granuloma with polyangiitis (EGPA).

Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis

Mepolizumab

Mepolizumab is an immunoglobulin G1κ monoclonal antibody that specifically targets the IL-5 antigen. IL-5 is a transmembrane glycoprotein with many functions and is highly expressed in hematological malignancies, including multiple myeloma tumors. IL-5 can regulate receptor-mediated adhesion, signaling, and cyclase and hydrolase activity. Mepolizumab inhibits tumor cell growth and induces broad-spectrum apoptosis by binding to IL-5 in a variety of mechanisms: Fc-mediated cross-linking, complement-dependent cytotoxicity, antibody-dependent cytotoxicity, and immune-dependent cell phagocytosis Lead tumor cell lysis.

Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis